rc48-adc
Locally Advanced Rectal Cancer (LARC)
brenner baruchantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Locally Advanced Rectal Cancer (LARC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
S-1 Tao Zhang | Phase 2 | CCC |
Tisleizumab Tao Zhang | Phase 2 | CCC |
Zanidatamab Emory University | Phase 2 | CCC |
Serplulimab First Affiliated Hospital of Wenzhou Medical University | Phase 2 | CCC |
Pyrotinib brenner baruch | Phase 2 | CCC |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →